Can-Fite Completes Dosing of All Patients in Phase III Psoriasis Study
FROM THE WIRE · GLOBENEWSWIRE.COM
The study evaluates oral Piclidenoson and last patient in the interim-analysis cohort completes treatment Ramat Gan, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralClinical trial milestone for a small biotech, with potential impact on the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01All 247 patients in the Phase III study of a small molecule have completed treatment.
- 02The study evaluates Piclidenoson for moderate-to-severe plaque psoriasis.
- 03The interim analysis is expected in Q1 2027.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets